7% FX adj. growth (cons 8%), EBITA -11% vs cons in a small quarter North America shown better demand...
Svaga intäkter men god kostnadskontroll förbättrar resultatet Midsummer rapporterade en svag nettoom...
Inga större överraskningar Bolaget är inne i en period där verksamheten drar förhållandevis begränsa...
~4% miss on NOI adj. for one-off LTV down 50 bps q-o-q to 53% Earnings capacity -4% due to divestmen...
Redeye reinforces its positive view of Hexatronic, following an encouraging outlook from several key...
Sales 0%, adj. EBITA -2% vs. cons, -4% org. sales Cons to lower '24e EBITA by 1-3% Strong cash flow ...
Redeye comments on GiG ahead of its Q1-results (due 7 May) where we expect continued solid performan...
Enrad AB:s nettoomsättning på ca 7,6 MSEK i kv1 2024 överträffade med god marginal på vår prognos på...
Loihde’s 2024 started of quite well and beat our expectations.
Etteplan publishes its Q1 results on 8th of May. We expect year-on-year revenue growth boosted by ac...
'24e-'26e EBITA down 7-1%... ...primarily due to changes in capitalisation policy '24e-'25e lease ad...
We cut '24e and '25e EBITDA by 17% and 8% Refocusing of Aurdel to improve margin stability '25e EV/E...
Rec. PTP 4% below ABGSCe CEPS est. down by 3-4% for '25-'26e Share trading at ~10% premium on '25e P...
M&A to drive growth while organically flat, EBITA margin to hold up H1 weakness in EMS industry, but...
Ahead of Taaleri's Q1 results, due on 7 May, we adjust our Q1 estimates to reflect expected fair val...
Ahead of Suominen’s Q1 report, due on 7 May, we maintain our estimates intact.
Redeye adjusts its estimates ahead of Arise’s Q1 report, which is due next week on 7 May.
Relais’ Commercial vehicle repair and maintenance company Raskone announced today acquisition of Ase...
STENOCARE published on May 2 the company’s Q1-report for 2024, showing progress.
Spago Nanomedical’s Phase I/IIa study, Tumorad-01, is progressing with a steady OPEX base in line wi...
